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A B S T R A C T
Background: The confirmatory diagnosis of pleural tuberculosis (pTB) remains challenging. The aim of
this study was to describe the clinical and epidemiological characteristics of pTB patients and assess the
yield of different diagnostic procedures in a low burden country with a high rate of immigrant
population.
Methods: All adult patients with pTB between 2007 and 2014 were studied retrospectively.
Results: One hundred and three out of 843 patients with tuberculosis had pTB. Fifty-three (54.1%) were
male, and the median age was 45 years (range 18–87 years). Fifty-two (50.49%) patients were immigrants.
A confirmed diagnosis was reached in 16 patients (15.5%) by microbiological studies of pleural effusion.
Lung involvement was demonstrated by sputum smear microscopy in 13/49 (26.5%), sputum GeneXpert
MTB/RIF test in 13/20 (65%), and sputum culture in 16/37 (43.2%). High-resolution computed tomography
(CT) showed lung involvement in 47.7% of the patients. The cure rate was 91.3% at the 1-year follow-up.
Three patients died, all of them within the first month after diagnosis.
Conclusions: The detection of lung involvement increased by two-fold when lung CT was used; this
correlated with the likelihood of finding a positive microbiological result on sputum sample testing.
Pleural microbiological studies had a low diagnostic yield, and sputum could have a complementary role.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) affects around nine million people and
accounts for 1.5 million deaths worldwide every year (World
Health Organization, 2014). In countries with a low incidence of TB,
the epidemiology and clinical presentation of the disease is
changing, with an increasing number of cases of extrapulmonary
involvement and a higher proportion of cases in non-native
patients (Baussano and Mercadante, 2013). According to the
European Union Statistical Agency, 3.4 million immigrants came to
the European Union (EU) in 2013, and Spain was in the top five* Corresponding author at: Departamento de Enfermedades Infecciosas, Hospital
Universitario Vall d’Hebron, Edificio General, 6a planta, Passeig Vall d’Hebron, 119-
129, CP 08035, Barcelona, Spain.
E-mail address: adsanche@vhebron.net (A. Sánchez-Montalvá).
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1201-9712/© 2018 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).countries receiving immigrants, taking in over 280 000 of them
(Migration and migrant population statistics, 2016). Due to this
persistent flow of immigrants and the increasing rates expected in
the coming years, TB will continue to be a major health issue in the
EU (European Centre for Diseases Prevention and Control/WHO
Regional Office for Europe, 2013).
After tuberculous lymphadenitis, pleural tuberculosis (pTB) is
the most common extrapulmonary presentation of TB disease. pTB
can appear as a complication of a primary disease or as a long-term
effect of dissemination occurring many years after the initial
infection (Davies and Pai, 2007). Factors such as age, chronic
diseases, and immunosuppressive conditions have been associated
with an increased incidence of pleural involvement (Gopi et al.,
2007). The incidence of TB in Barcelona in 2015 was 14.9 cases per
100 000 population, with 10% of pleural involvement (Informea-
nual, 2015).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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confirmed bacteriological diagnosis; hence many treatments are
started based on a presumed diagnosis (Light, 2010; Richter et al.,
1994). The percentage of confirmed diagnosis varies widely (from
12% to 80%) depending on the study location and prevalence of the
disease (Porcel et al., 2015; Na, 2014). Although molecular biology
methods are being generalized for samples other than sputum, the
diagnostic yield of molecular biology studies on pleural effusion is
variable and usually lower than that for sputum (Trajman et al.,
2014; Porcel et al., 2013).
Pulmonary involvement in pTB has been described in many
series, and it is suggested to approach 50% in studies using high-
resolution computed tomography (CT) (Kim et al., 2006). Induced
sputum or even bronchoscopy may increase the yield of the culture
diagnosis of pTB, which is extremely useful in settings with a high
burden of resistance to the first-line anti-TB drugs (Conde et al.,
2003).
The objective of this study was to describe the clinical and
epidemiological characteristics of patients with pTB in a low
incidence burden area and establish the yield of the different
microbiological techniques.
Materials and methods
Study population
This was a retrospective observational study performed at
the Vall d’Hebron University Hospital, a tertiary reference
centre included in the International Health Program of the
Catalan Health Institute (PROSICS), Barcelona, Spain. Patients
older than 18 years of age with a diagnosis of pTB between
January 2007 and December 2014 were included. Epidemiologi-
cal, clinical, and microbiological information was obtained from
all patients through a review of the medical records. The
diagnostic approach and the treatment were at the discretion of
the treating physician.
Pleural tuberculosis definitions
The diagnosis of pTB was classified as bacteriologically
confirmed or probable. Bacteriologically confirmed pTB was
defined as a positive Ziehl–Neelsen (ZN) smear, positive culture,
and/or positive PCR assay from a pleural sample. Probable pTB was
considered if a positive response to anti-TB drugs was found and
one of the following conditions was present: (1) biochemical
diagnosis: pleural exudates with lymphocyte predominance and
adenosine deaminase (ADA) level higher than 35 IU/L; (2)
histopathological sample showing necrotizing granuloma and/or
caseous necrosis; (3) pleural effusion in a patient with confirmed
TB at any other location. A positive response to treatment was
defined as symptom resolution and pleural effusion improvement
by at least 90% of the initial assessment. Pleural biopsy was
performed at the discretion of the attending physician. The main
reasons for performing a biopsy were a high risk of multidrug-
resistant TB, high suspicion of an alternative diagnosis, and a poor
clinical course.
Microbiological studies
Pleural samples were examined microscopically using ZN stain.
All samples were cultured and incubated in a BACTEC MGIT 960
(Becton Dickinson Diagnostic Systems, Baltimore, MD, USA). Drug
susceptibility testing of Mycobacterium tuberculosis was done using
the BACTEC MGIT 960 SIRE Kit for the first-line drugs: streptomy-
cin, isoniazid, rifampicin, ethambutol, and pyrazinamide (Kent and
Kubica, 1985). When resistance to any first-line drug was detected,the drug susceptibility test was broadened to the following
antibiotics: amikacin, capreomycin, streptomycin, ethionamide,
moxifloxacin, and ofloxacin. Molecular biology testing was done
with the GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA)
on pleural samples.
Imaging assessment
A chest X-ray was performed for all patients. The need for a
high-resolution CT scan was at the discretion of the treating
physician. Lung parenchyma findings suggestive of TB, such as
nodules, infiltration, cavities, and pleural thickening, were
recorded.
Statistical analysis
Categorical variables are presented as the absolute number and
proportion, and continuous variables are expressed as the median
and range. The Chi-square test or Fisher’s exact test was used to
compare the distribution of categorical variables, as appropriate,
and the Mann–Whitney U-test or Student t-test was used to assess
continuous variables (following evaluation for a normal distribu-
tion through the Kolmogorov–Smirnov test). Results were
considered statistically significant if the two-tailed p-value was
<0.05. IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY,
USA) was used for the statistical analyses.
Ethical considerations
The study protocol was approved by the Institutional Review
Board of Vall d’Hebron University Hospital (Barcelona, Spain). An
exemption from obtaining informed consent was granted.
Procedures were performed in accordance with the ethical
standards laid down in the Declaration of Helsinki as revised in
2012 in Fortaleza, Brazil (World Medical Association, 2016).
Results
Of an overall 843 patients with TB, a total of 103 patients
fulfilled the inclusion criteria for pTB. The median age of the study
population was 45 years (range 18–87 years) and 51.4% were male.
Twenty (19.4%) of the patients had an immunosuppressant
condition, including seven patients with an HIV infection. More
data regarding patient characteristics and epidemiological infor-
mation are shown in Table 1. Figure 1 depicts the number of total
TB and pTB cases per year.
Regarding symptoms, the chief complaints were fever (n = 83,
80.5%), pleuritic chest pain (n = 70, 67.9%), cough (n = 56, 54.3%),
general weakness (n = 41, 39.8%), dyspnoea (n = 39, 37.8%), diapho-
resis (n = 37, 35.9%), and weight loss (n = 33, 33.9%). The median
duration of symptoms was 21 days (range 3–365 days). Four
patients (3.8%) had a personal history of previous TB (two
pulmonary TB and two pTB). More clinical and epidemiological
information is detailed in Table 2.
When analyzing the biochemical characteristics of the pleural
effusion, 14 of 97 cases (14.4%) did not have a lymphocytic
predominance in pleural effusion and five of 101 cases (4.95%) had
an ADA concentration below the suggested limit to consider the
diagnosis. All of these cases had a confirmed TB diagnosis by
culture or a pleural biopsy showing granulomas. Table 3 shows the
diagnostic yield according to biochemical characteristics of the
pleural effusion.
A confirmed diagnosis was made in 16 (15.5%) patients: 14 by
microbiological studies of pleural effusion and six by microbiolog-
ical studies of pleural biopsy, four of them with negative pleural
effusion microbiological studies. The diagnosis for 87 patients
Figure 1. Number of pleural TB and total cases of TB at Vall d’Hebron University Hospital. Barcelona, Spain 2007–2014.
Table 1
Demographic characteristics of the patients (N = 103).
Variable Number (%)
Sex (male) 53 (51.5%)
Age (years), median (range) 45 (18–87)
Foreign born 52 (51.5%)
Latin America 20 (38.4%)
Africa 14 (26.9%)
Asia 11 (21.2%)
Eastern Europe 7 (13.4%)
Duration of stay in Spain prior to diagnosis (years), median (range) 3 (0–25)
Immunosuppressive conditions 20 (19.4%)
HIV infection 7 (6.7%)
Autoimmune diseases 4 (3.9%)
Steroid therapy 4 (3.9%)
Anti-TNF inhibitor therapy 2 (1.9%)
Liver transplantation 1 (0.9%)
Kidney replacement therapy 1 (0.9%)
TNF, tumour necrosis factor.
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techniques, the yield was superior in sputum and pleural biopsy
samples than in pleural effusion (Table 4).
Twenty-four (23.3%) patients had lung involvement as seen on
chest X-ray. High-resolution CT was done for 57 (55.34%) patients.
Twenty-seven out of 57 (47.4%) showed lung involvement on high-
resolution CT scan, with 16 patients having any tomographic
finding of tuberculous lung involvement not visualized in the X-
ray, thereby increasing the diagnostic yield of having lung
compromise by 2.3 times. Moreover, patients with lung compro-
mise had a higher yield on diagnosis in the sputum sample,
compared with those who did not have lung compromise (72.2% vs.
25%; p = 0.002).
In the drug susceptibility test assessment, no resistance to anti-
TB drugs was found. Thirty-nine (37.8%) patients developed any
adverse effect related to the anti-TB drugs. The most frequent were
nausea (n = 8, 7.7%), mild hepatic cytolysis (n = 7, 6.7%), and
cholestasis (n = 5, 4.8%).The great majority of therapy regimens (96%) included the
standard four-drug treatment including isoniazid, rifampicin,
pyrazinamide, and ethambutol. Only four patients were treated
with a fluoroquinolone during follow-up, with side effects being
the cause of the switch in all cases. The median duration of the
treatment was 6 months (confidence interval interquartile range
5.5–8.5 months).
After 1 year of follow-up, 94 (91.3%) patients were cured, five
were lost to follow-up, and four had died. Three of the deaths
occurred in the hospital within the first month after the diagnosis.
In brief, one patient suffered a haemophagocytic syndrome
associated to the TB, another patient had multifactorial encepha-
lopathy (age, renal replacement therapy, TB infection, and anti-TB
treatment) that led to death, and one cirrhotic patient developed a
fulminant hepato-renal syndrome concomitant with the TB
infection. The remaining patient died of reasons unrelated to TB
during follow-up. There was no case of relapse during the study
period.
Table 2
Epidemiological and clinical data of patients with pleural TB (2007–2014)a.
Overall Spanish (n = 51) Immigrant (n = 52) p-Value
Sex, male 53 (51.4%) 26 (50.9%) 27 (51.9%) 0.92
Age (years) 45 (18–87) 46.9 (18–87) 34.3 (18–77) <0.001
Time to consultation (days) 21 (3–365) 28 (4–365) 20 (3–180) 0.31
Extrapleural involvement 31 (30%) 25 (49%) 24 (46.2%) 0.85
HIV co-infection 7 (6.7%) 5 (9.8%) 2 (3.8%) 0.27
Immunosuppressionb 10 (9.7%) 6 (11.7%) 4 (7.6%) 0.52
Positive TST 45 (83.3%) 19 (73.1%) 26 (96.3%)
Empiric anti-TB treatment 87 (84.4%) 42 (82.3%) 45 (86.5%) 0.37
Confirmed pleural TB 16 (15.5%) 9 (17.6%) 7 (13.5%) 0.55
Pleural biopsy 17 (16.5%) 10 (19.6%) 7 (13.4%) 0.28
TB, tuberculosis; TST, tuberculin skin test.
a Data are presented as the number (percentage) or the median (range).
b Immunosuppression includes autoimmune diseases and/or immunosuppressant agents, corticoid therapy, biological therapy, and transplantation.
Table 3
Proportion of diagnosis according to characteristics of the pleural effusion.
Samples/methods Total Confirmed Probable p-Value
ADA-positivea in pleural effusion 96/101 (95%) 14/16 (87.5%) 82/85 (96.5%) 0.177
Pleural exudates 98/100 (98%) 15/16 (93.8%) 83/84 (98.8%) 0.296
Lymphocytic pleural effusion 83/97 (85.6%) 11/16 (68.8%) 72/81 (88.9%) 0.052
ADA-positivea + lymphocytic effusion + pleural exudate 77/96 (80.2%) 10/16 (62.5%) 67/80 (83.8%) 0.081
ADA, adenosine deaminase.
a ADA > 35 IU/IU/L.
Table 4
Diagnostic accuracy of the different techniques employed.
Pleural effusion Sputum Pleural biopsy
Ziehl–Neelsen Culture PCR Ziehl–Neelsen Culture PCR Any diagnostic finding
Total 2/79 10/60 8/52 13/49 16/37 13/20 4/17a
7/17b
Diagnostic
accuracy
2.5% 16.6% 15.38% 26.5% 43.2% 65% 23.53%a
41.2%b
a Positive smear, positive culture, or positive molecular biology test.
b Granuloma or caseous necrosis.
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In this study, the clinical and epidemiological characteristics of
pTB in a tertiary hospital of a low burden country, over eight
consecutive years, are described. In Vall d’Hebron University
Hospital, pTB accounts for 12.2% of the total number of TB cases. Of
note, half of the cohort was foreign-born, mainly from Latin
America and Africa (in concordance with the immigrant popula-
tion in Barcelona). The pTB diagnosis was mainly based on clinical
information, biochemical characteristics of the pleural effusion,
and microbiological results obtained for another location, with
only 22 (21.3%) having a microbiological confirmatory result from a
pleural sample. Sputum samples showed a good yield, especially in
patients with lung involvement found on imaging.
From a clinical perspective, these patients were mostly young
adults, with no important co-morbid predisposing conditions, and
with the classical signs and symptoms of fever, pleuritic chest pain,
and cough. The duration of symptoms varied from 3 days to 1 year.
The yield of biochemical pleural effusion characteristics was
high, with an exudative effusion being the most common finding.
In a recent study of 548 cases performed by Sahn et al. (2013) the
diagnosis had 100% specificity if the pleural effusion met the
following criteria: protein >5 g/dl, lymphocyte count > 80%, and
ADA > 45 mg/dl IU/L (sensitivity of 35%). In the patients included in
the present study, considering protein > 3.5 g/dl, lymphocytepredominance > 50%, and ADA > 35 mg/dl, IU/L the three condi-
tions were present in 80.2% (77/96 cases).
The yield of PCR on pleural effusion was lower (seven positive
cases out of 51, 13.7%) than that observed for PCR on sputum (13
positive cases out of 20, 65%). According to other publications, the
sensitivity of the GeneXpert assay on pleural effusion is usually low
(around 25%), with high specificity (around 95%) (Lusiba et al.,
2014). The reasons for this are not clear, but could probably be
attributed to the presence of PCR inhibitors in pleural fluid and a
low bacillary load (Du et al., 2015).
Regarding pleural biopsy, despite being considered the most
useful technique to confirm a suspected diagnosis, with rates of
positivity between 60% and 95%, the indication for this in pTB is not
clear (Kirsch et al., 1997). Performing a pleural biopsy is not
without risks, although direct injury to the adjacent organs (liver,
kidneys, spleen) is very rare. The incidence of pneumothorax with
a closed needle is variable and depends on the operator, but could
be between 8% and 18% (Gouda et al., 2006). In the present study,
pleural biopsy was performed at the discretion of the attending
physician and the yield was 64.7% (11/17 cases). The procedure was
performed in selected patients, in whom the diagnosis was not
reached with other procedures. For this reason, the different yields
of the diagnostic techniques should be interpreted with caution.
Interestingly, in this study, the sputum yield remained high
even in the absence of involvement seen on chest X-ray. In a
previous report Conde et al. (2003), found a yield in induced
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pTB and no apparent lung involvement on chest X-ray; thus
sputum induction in patients with pleural effusion provides an
invaluable opportunity to confirm a probable diagnosis and to
perform a susceptibility study to guide treatment.
From our perspective, we consider it justified to start anti-TB
treatment in the case of an immigrant from a high incidence TB
country presenting with a febrile process accompanied by an
exudative pleural effusion with a high number of lymphocytes and a
high ADA level, unless there is a high risk of multidrug-resistant TB or
an alternative diagnosis is highly probable. In this situation, a pleural
biopsy should be considered. In fact, the diagnosis wasprobable in 87
(84.5%) patients in the study cohort and treatment was started on
this assumption, leading to a 100% therapeutic response.
In the study cohort, the prognosis of the disease was favourable
in the majority of patients and the cure rate was >90%, which is in
concordance with the global plan to end TB (the STOP TB
programme) (The paradigm Shift, 2015). The deaths that occurred
were not associated with the pleural involvement itself and were
related to multi-organ compromise, co-morbid conditions, and
immunosuppression. In other series, as in this study, mortality has
usually been associated with advanced age and co-morbid
conditions not related to TB (Efsen et al., 2014).
The limitations of this study include those inherent to the
retrospective design. It should be noted that there was variability
among physician criteria and a lack of molecular biology tests at
the beginning of the study period. Moreover, pTB is a disease that is
challenging to confirm with a difficult-to-establish gold standard
diagnosis, hindering the assessment of diagnostic methods.
In conclusion, pTB represents 12% of all TB diagnoses at Vall
d’Hebron University Hospital, with half of the cases diagnosed in
immigrant patients. A confirmed diagnosis was achieved in 21.3%
of cases using pleural samples. The detection of lung involvement
increases by two-fold when lung CT is used, which correlated with
the likelihood of finding a positive microbiological result in the
sputum sample. Pleural microbiological studies had low diagnostic
yield, and sputum samples, even in the absence of X-ray
abnormalities, may support the diagnosis and provide information
on drug susceptibility of the bacillus.
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